CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Results of Operations and Financial Condition
Item 2.02 and in Exhibit 99.1 attached to this Current Report on
Form 8-K is being furnished to the Securities and Exchange
Commission and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended
(theExchange Act), or otherwise subject to the liabilities of
that Section, or incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, except as shall
be expressly set forth in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
|
99.1 |
Press release issued by Cesca Therapeutics Inc. on May 11, |
About CESCA THERAPEUTICS INC. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood. CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Recent Trading Information
CESCA THERAPEUTICS INC. (NASDAQ:KOOL) closed its last trading session down -0.07 at 3.12 with 14,814 shares trading hands.
